— ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) reported Q4 2019 loss of $0.34 per share, vs. $0.36 expected. — Revenue grew 65% to $98.3 million vs. $97.76 million expected. — For FY20, NUPLAZID sales is expected to be between $440 million and $470 million. — For fiscal 2020, GAAP R&D expense is expected to be between […]
“— ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) reported Q4 2019 loss of $0.34 per share, vs. $0.36 expected. — Revenue grew 65% to $98.3 million vs. $97.76 million expected. — For FY20, NUPLAZID sales is expected to be between $440 million and $470 million. — For fiscal 2020, GAAP R&D expense is expected to be between […]
· February 26, 2020
— ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) reported Q4 2019 loss of $0.34 per share, vs. $0.36 expected.
— Revenue grew 65% to $98.3 million vs. $97.76 million expected.
— For FY20, NUPLAZID sales is expected to be between $440 million and $470 million.
— For fiscal 2020, GAAP R&D expense is expected to be between $270 and $285 million and GAAP SG&A expense is expected to be between $440 and $460 million.
— ACAD shares rose about 4% following the earnings announcement.
Get access to timely and accurate verbatim transcripts that are published within hours of the event
